309 results
Page 4 of 16
8-K
EX-10.5
vke4v1r
20 Dec 22
Departure of Directors or Certain Officers
4:15pm
8-K
EX-10.2
cm1sziqwqjkd0uk
20 Dec 22
Departure of Directors or Certain Officers
4:15pm
8-K
EX-10.4
9zvx9
20 Dec 22
Departure of Directors or Certain Officers
4:15pm
8-K
EX-10.7
lrcrz8tn
20 Dec 22
Departure of Directors or Certain Officers
4:15pm
8-K
EX-10.6
ipo9pgs673oe4tb64
20 Dec 22
Departure of Directors or Certain Officers
4:15pm
8-K
EX-10.1
x2zx8jyy95u
9 Nov 22
Entry into a Material Definitive Agreement
8:30am
8-K
EX-99.2
o8xdlgs6 jn2dv
9 Nov 22
Entry into a Material Definitive Agreement
8:30am
8-K
EX-4.1
cj7hb0 2hmufn3e
9 Nov 22
Entry into a Material Definitive Agreement
8:30am
424B5
5u72x9p45
8 Nov 22
Prospectus supplement for primary offering
9:50pm
8-K
EX-99.1
lsy34l8p3i 85zq
24 Oct 22
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients
9:41am
424B5
56ycpanqa92bwacy7
29 Jul 22
Prospectus supplement for primary offering
5:09pm
424B5
a5rzckfp4iwny2v7nj
14 Jun 22
Prospectus supplement for primary offering
5:19pm
424B5
t7a9svc
14 Jun 22
Prospectus supplement for primary offering
5:18pm
UPLOAD
worwcd3bt9uuq6x1
2 Jun 22
Letter from SEC
12:00am